![Magnus Nylén](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Magnus Nylén
Director/Miembro de la Junta en
SELECTIMMUNE PHARMA AB (PUBL)
.
Perfil
Magnus Nylén is currently Director at Hamlet BioPharma AB starting in 2025.
Mr. Nylén is also Director at SelectImmune Pharma AB since 2022.
Additionally, Mr. Nylén has been Owner at Partner Fondkommission AB since 2013.
Mr. Nylén completed undergraduate education at Boston University.
Cargos activos de Magnus Nylén
| Empresas | Cargo | Inicio |
|---|---|---|
| SELECTIMMUNE PHARMA AB (PUBL) | Director/Miembro de la Junta | 23/11/2022 |
| HAMLET PHARMA AB (PUBL) | Director/Miembro de la Junta | 11/03/2025 |
Partner Fondkommission AB
 Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Corporate Officer/Principal | 01/01/2013 |
Formación de Magnus Nylén.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
6
Relaciones de 1er grado
4
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Partner Fondkommission AB
Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Finance |
Hamlet BioPharma AB
 Hamlet BioPharma AB Pharmaceuticals: MajorHealth Technology Engages in the research and development of pharmaceutical products specifically for cancer patients | Health Technology |
SelectImmune Pharma AB
 SelectImmune Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops and manufactures immune enhancers to complement antibiotics | Health Technology |
- Bolsa de valores
- Insiders
- Magnus Nylén
Elige MarketScreener 
